Adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people requiring surgery for chronic pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (proportion) · people requiring surgery for chronic pancreatitis
It is very uncertain whether duodenum‐preserving pancreatic resection changes adverse events (proportion) compared with pancreaticoduodenectomy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (number of adverse events) · people requiring surgery for chronic pancreatitis
It is very uncertain whether duodenum‐preserving pancreatic resection changes adverse events (number of adverse events) compared with pancreaticoduodenectomy (very low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review